Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Rationale Ayahuasca is a South American psychoactive beverage that contains the naturally occurring psychedelic agent N,N-dimethyltryptamine (DMT). This "tea" has been used for centuries in religious and medicinal contexts in the rain forest areas of South America and is presently gaining the attention of psychedelic users in North America and Europe. Objectives In the present study, the psychological effects and tolerability of ayvahuasca were assessed. Methods Three increasing doses of encapsulated freeze-dried ayahuasca (0.5, 0.75, and 1.0 mg DMT/kg body weight) were administered to six healthy male volunteers with prior experience in the use of this tea, in a single-blind crossover placebo-controlled clinical trial. Results Ayahuasca produced significant dose-dependent increases in five of the six subscales of the Hallucinogen Rating Scale, in the LSD, MBG, and A scales of the Addiction Research Center Inventory, and in the "liking", "good effects" and "high" visual analogue scales. Psychological effects were first noted after 30-60 min, peaked between 60-120 min, and were resolved by 240 min. The tea was well tolerated from a cardiovascular point of view, with a trend toward increase for systolic blood pressure. Modified physical sensations and nausea were the most frequently reported somatic-dysphoric effects. The overall experience was regarded as pleasant and satisfactory by five of the six volunteers, while one volunteer experienced an intensely dysphoric reaction wi…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ayahuasca has been demonstrated to be safe in naturalistic (35, 108) and clinical settings, across varying dosages and multiple administrations (26, 109–112).”
From Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol (2025) · cites this paper as [109]
In the citing paper
“Ayahuasca was found to significantly raise the systolic and diastolic blood pressure by 35 Hgmm and the pulse rate by 26 bpm in a 2 min time interval while the rate of increase declines upon repeated intake (Riba et al., 2001).”
From The therapeutic potentials of Ayahuasca: possible effects against various diseases of civilization (2016) · cites this paper as Riba et al., 2001
Citations
Cites
(1970) · Cited by 24,983
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 1×
“…and cognitive modifications induced by these agents, as in another study psilocybin's subjective effects were found to be increased rather than reverted by the D 2 receptor antagonist, haloperidol , while they were effectively counteracted by ketanserin and risperidone (Vollenweider et al. 1998).”
BackgroundLane, R. D., Reiman, E. M., Axelrod, B., Yun, L.-S., Holmes, A., & Schwartz, G. E. (1998) · Journal of Cognitive Neuroscience · doi:10.1162/089892998562924 · Cited by 671
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & McKenney, J. D. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 631
AGHAJANIAN, G. K., & MAREK, G. J. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00051-8 · Cited by 514
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444 · cited 1×
“…revealed patterns of increased metabolism throughout the brain, and more specifically in the prefrontal cortices, particularly in the right hemisphere, in healthy volunteers after dosing with psilocybin (Vollenweider et al. 1997; Gouzoulis- Mayfrank et al. 1999b) and mescaline (Hermle et al. 1992).”
BackgroundSerotonin receptors in the human brain—III. Autoradiographic mapping of serotonin-1 receptors
Pazos, A., Probst, A., & Palacios, J. M. (1987) · Neuroscience · doi:10.1016/0306-4522(87)90326-5 · Cited by 436
McKenna, D. J., Towers, G. H. N., & Abbott, F. (1984) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(84)90003-5 · Cited by 398 · cited 8×
“When compared with IV DMT, it is reasonable to assume that the reversible MAO-inhibiting properties of harmine and harmaline leads to a transient increase in endogenous monoamines, in addition to DMT's own cardiovascular effects.”
BackgroundMethodResultInfluentialHuman psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil.
GROB, C. S., McKENNA, D. J., CALLAWAY, J. C., BRITO, G. S., NEVES, E. S., OBERLAENDER, G., SAIDE, O. L., LABIGALINI, E., TACLA, C., MIRANDA, C. T., et al. (1996) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199602000-00004 · Cited by 338
Self-citation
Cited by
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649
Osório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488
Self-citationPalhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049882 · Cited by 390
Self-citationBarrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M. S., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116678781 · Cited by 366
“…of Consciousness Inventory (Pekala, 1986), the Minnesota Multiphasic Personality Inventory (Belleville, 1956), the States of Consciousness Questionnaire (Griffiths et al., 2006, 2011), and the Addiction Research Center Inventory (Griffiths et al., 2006, 2011; Haertzen, 1966; Riba et al., 2001).”
Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada
Thomas, G., Lucas, P., Capler, N., Tupper, K., & Martin, G. (2013) · Current Drug Abuse Reviews · doi:10.2174/15733998113099990003 · Cited by 330
McKenna, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.03.002 · Cited by 321
Bouso, J. C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Ribeiro Barbosa, P. C., Alcázar-Córcoles, M. Á., Araújo, W. S., Barbanoj, M. J., Fábregas, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042421 · Cited by 313
Self-citationdos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306
Self-citationClassical psychedelics for the treatment of depression and anxiety: A systematic review
Muttoni, S., Ardissino, M., & John, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.076 · Cited by 256
Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids.
Gable, R. S. (2007) · Addiction · doi:10.1111/j.1360-0443.2006.01652.x · Cited by 244
“0 mg/kg were shown to induce peak increases in heart rate and blood pressure at about one-third that of intravenous DMT after 90 and 120 minutes [3,20].”
BackgroundInfluentialThe therapeutic potentials of Ayahuasca: possible effects against various diseases of civilization
Frecska, E., Bokor, P., & Winkelman, M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00035 · Cited by 242
“Ayahuasca was found to significantly raise the systolic and diastolic blood pressure by 35 Hgmm and the pulse rate by 26 bpm in a 2 min time interval while the rate of increase declines upon repeated intake (Riba et al., 2001).”
BackgroundIncreased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant
Riba, J., Romero, S., Grasa, E., Mena, E., Carrió, I., & Barbanoj, M. J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0358-7 · Cited by 241
“Compared with intravenous DMT as described by Strassman et al. (1994), HRS scores after the present ayahuasca dose fell between those reported after 0.2 and 0.4 mg/kg IV DMT.”
MethodResultInfluentialSelf-citationSeeing with the eyes shut: neural basis of enhanced imagery following ayahuasca ingestion.
de Araujo, D. B., Ribeiro, S., Cecchi, G. A., Carvalho, F. M., Sanchez, T. A., Pinto, J. P., de Martinis, B. S., Crippa, J. A., Hallak, J. E. C., & Santos, A. C. (2012) · Human Brain Mapping · doi:10.1002/hbm.21381 · Cited by 239
Ayahuasca: pharmacology, neuroscience and therapeutic potential
Domínguez-Clavé, E., Soler, J., Elices, M., Pascual, J. C., Álvarez, E., de la Fuente Revenga, M., Friedlander, P., Feilding, A., & Riba, J. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.03.002 · Cited by 226
Self-citationHallucinogens and dissociative agents naturally growing in the United States
Halpern, J. H. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.03.003 · Cited by 218
Bouso, J. C., Palhano-Fontes, F., Rodríguez-Fornells, A., Ribeiro, S., Sanches, R., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., & Riba, J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.008 · Cited by 218
“Interestingly, DMT is rendered orally active by the MAO-inhibiting β-carboline alkaloids found in the other plant, B. caapi, used in ayahuasca (Riba et al., 2001).”
InfluentialSelf-citationUthaug, M. V., van Oorsouw, K., Kuypers, K. P. C., van Boxtel, M., Broers, N. J., Mason, N. L., Toennes, S. W., Riba, J., & Ramaekers, J. G. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4988-3 · Cited by 212
Self-citationSantos, R. G., Landeira-Fernandez, J., Strassman, R. J., Motta, V., & Cruz, A. P. M. (2007) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2007.04.012 · Cited by 205
Soler, J., Elices, M., Franquesa, A., Barker, S., Friedlander, P., Feilding, A., Pascual, J. C., & Riba, J. (2016) · Psychopharmacology · doi:10.1007/s00213-015-4162-0 · Cited by 209
Self-citationClinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
“Later research has confirmed and elaborated on the medical safety and pharmacology of ayahuasca use (Barbosa et al., 2012; Bouso et al., 2012; Dos Santos et al., 2007, 2011, 2012; Gable, 2007; Riba et al., 2001; Riba & Barbanoj, 2005).”
Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
Kuypers, K. P. C., Riba, J., de la Fuente Revenga, M., Barker, S., Theunissen, E. L., & Ramaekers, J. G. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4377-8 · Cited by 201
“Acute subjective effects usually start between 45 and 60 min post-administration and include visionary experiences with more intense emotions and increased rates of thinking when the eyes are closed (Riba et al. 2001, 2003).”
BackgroundSelf-citationHamill, J., Hallak, J., Dursun, S. M., & Baker, G. (2019) · Current Neuropharmacology · doi:10.2174/1570159x16666180125095902 · Cited by 178
Sampedro, F., de la Fuente Revenga, M., Valle, M., Roberto, N., Domínguez-Clavé, E., Elices, M., Luna, L. E., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx036 · Cited by 200
Self-citationUnifying Theories of Psychedelic Drug Effects
Swanson, L. R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00172 · Cited by 181
Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies
dos Santos, R. G., Bouso, J. C., & Hallak, J. E. C. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316689030 · Cited by 168
Valle, M., Maqueda, A. E., Rabella, M., Rodríguez-Pujadas, A., Antonijoan, R. M., Romero, S., Alonso, J. F., Mañanas, M. À., Barker, S., Friedlander, P., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.012 · Cited by 173
Self-citationdos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2015-1701 · Cited by 160
Pattern of use and subjective effects of Salvia divinorum among recreational users
González, D., Riba, J., Bouso, J. C., Gómez-Jarabo, G., & Barbanoj, M. J. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.04.001 · Cited by 163
Self-citationHerbal remedies for anxiety – a systematic review of controlled clinical trials
Ernst, E. (2005) · Phytomedicine · doi:10.1016/j.phymed.2004.11.006 · Cited by 166
Ayahuasca and the process of regulation in Brazil and internationally: Implications and challenges
Labate, B. C., & Feeney, K. (2012) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2011.06.006 · Cited by 146
Sklerov, J., Levine, B., Moore, K. A., King, T., & Fowler, D. (2005) · Journal of Analytical Toxicology · doi:10.1093/jat/29.8.838 · Cited by 144
dos Santos, R. G., Valle, M., Bouso, J. C., Nomdedéu, J. F., Rodríguez-Espinosa, J., McIlhenny, E. H., Barker, S. A., Barbanoj, M. J., & Riba, J. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823607f6 · Cited by 136
Self-citationPharmacology of ayahuasca administered in two repeated doses
dos Santos, R. G., Grasa, E., Valle, M., Ballester, M. R., Bouso, J. C., Nomdedéu, J. F., Homs, R., Barbanoj, M. J., & Riba, J. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2434-x · Cited by 141
“Vomiting is commonly reported for liquid ayahuasca but rarely observed after single dose administration of the encapsulated freeze-dried formulation (Riba et al. 2001a; Riba et al. 2003).”
BackgroundMethodResultInfluentialSelf-citationViol, A., Palhano-Fontes, F., Onias, H., de Araujo, D. B., & Viswanathan, G. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-06854-0 · Cited by 146
Morales-Garcia, J. A., Calleja-Conde, J., Lopez-Moreno, J. A., Alonso-Gil, S., Sanz-SanCristobal, M., Riba, J., & Perez-Castillo, A. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01011-0 · Cited by 138
Self-citationDevelopments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatment
Brierley, D. I., & Davidson, C. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.001 · Cited by 156
Galvão-Coelho, N. L., Marx, W., Gonzalez, M., Sinclair, J., de Manincor, M., Perkins, D., & Sarris, J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05719-1 · Cited by 137
Riba, J., Anderer, P., Jané, F., Saletu, B., & Barbanoj, M. J. (2004) · Neuropsychobiology · doi:10.1159/000077946 · Cited by 130
Self-citationLafrance, A., Loizaga-Velder, A., Fletcher, J., Renelli, M., Files, N., & Tupper, K. W. (2017) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2017.1361559 · Cited by 125
dos Santos, R. G., Balthazar, F. M., Bouso, J. C., & Hallak, J. E. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116652578 · Cited by 125
“Alonso et al. (2015) assessed the subjective acute effects of a single dose of encapsulated freeze-dried AYA (0.75 mg DMT/kg) in 10 healthy volunteers in a double-blind, randomized, crossover study.”
InfluentialRiba, J., Anderer, P., Morte, A., Urbano, G., Jané, F., Saletu, B., & Barbanoj, M. J. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01609.x · Cited by 125
Self-citationSubacute effects of the psychedelic ayahuasca on the salience and default mode networks
Pasquini, L., Palhano-Fontes, F., & Araujo, D. B. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120909409 · Cited by 119
Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey
Bouso, J. C., Andión, Ó., Sarris, J. J., Scheidegger, M., Tófoli, L. F., Opaleye, E. S., Schubert, V., & Perkins, D. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000438 · Cited by 118
“75mg/DMT/kg), and high (1mg/DMT/kg) doses of ayahuasca [40, 41], subjects scored active doses higher than a placebo in terms of the Visual Analogue Scales “liking,” and the ayahuasca was well tolerated.”
BackgroundWhen the Endogenous Hallucinogenic Trace Amine N,N-Dimethyltryptamine Meets the Sigma-1 Receptor
Su, T.-P., Hayashi, T., & Vaupel, D. B. (2009) · Science Signaling · doi:10.1126/scisignal.261pe12 · Cited by 110
Uthaug, M. V., Mason, N. L., Toennes, S. W., Reckweg, J. T., de Sousa Fernandes Perna, E. B., Kuypers, K. P. C., van Oorsouw, K., Riba, J., & Ramaekers, J. G. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05817-8 · Cited by 112
“This leads to intense alterations in perception and sensory integration and the induction of a highly altered state of consciousness (McKenna 2004; Palhano-Fontes et al. 2015; Riba et al. 2001; Tupper 2008).”
BackgroundSelf-citationHealth status of ayahuasca users
Barbosa, P. C. R., Mizumoto, S., Bogenschutz, M. P., & Strassman, R. J. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1383 · Cited by 112
McCulloch, D. E.-W., Knudsen, G. M., Barrett, F. S., Doss, M. K., Carhart-Harris, R. L., Rosas, F. E., Deco, G., Kringelbach, M. L., Preller, K. H., Ramaekers, J. G., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104689 · Cited by 120
Psychological and neuropsychological assessment of regular hoasca users
Barbosa, P. C. R., Strassman, R. J., da Silveira, D. X., Areco, K., Hoy, R., Pommy, J., Thoma, R., & Bogenschutz, M. (2016) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2016.09.003 · Cited by 105
“, heart rate and blood pressure) to hoasca are modest, and most psychological and physiological parameters return to baseline levels by 4 to 6 h [5].”
Riba, J., McIlhenny, E. H., Bouso, J. C., & Barker, S. A. (2015) · Drug Testing and Analysis · doi:10.1002/dta.1685 · Cited by 97
Self-citationSoler, J., Elices, M., Dominguez-Clavé, E., Pascual, J. C., Feilding, A., Navarro-Gil, M., García-Campayo, J., & Riba, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00224 · Cited by 102
“On a molecular level, DMT has affinity for 5-HT2A and 5-HT1A binding sites, where it acts as an agonist or partial agonist (Riba et al., 2001; Carbonaro et al., 2015).”
BackgroundSelf-citationThe acute effects of classic psychedelics on memory in humans
Healy, C. J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05756-w · Cited by 106
Riba, J., McIlhenny, E. H., Valle, M., Bouso, J. C., & Barker, S. A. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1344 · Cited by 93
Self-citationSerotonergic psychedelics temporarily modify information transfer in humans.
Alonso, J. F., Romero, S., Mañanas, M. À., & Riba, J. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv039 · Cited by 101
“Scores on the HRS and APZ questionnaires were compared between placebo and ayahuasca using Student’s t tests followed by correction for multiple comparisons using the false discovery rate.”
InfluentialSelf-citationCaudevilla-Gálligo, F., Riba, J., Ventura, M., González, D., Farré, M., Barbanoj, M. J., & Bouso, J. C. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431752 · Cited by 98
Self-citationBouso, J. C., Fábregas, J. M., Antonijoan, R. M., Rodríguez-Fornells, A., & Riba, J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3167-9 · Cited by 96
Self-citationNunes, A. A., dos Santos, R. G., Osório, F. L., Sanches, R. F., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2016.1188225 · Cited by 93
Safety and Side Effects of Ayahuasca in Humans—An Overview Focusing on Developmental Toxicology
Guimarães dos Santos, R. (2013) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2013.763564 · Cited by 87
Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications
Kraehenmann, R. (2017) · Current Neuropharmacology · doi:10.2174/1573413713666170619092629 · Cited by 92
“Although elevated mood states and pleasant feelings are most frequent [94-96], anxiety reactions may occur, especially at higher doses when normal cognitive frames of reference are diminished (“dread of ego dissolution”) [95].”
BackgroundYritia, M., Riba, J., Ortuño, J., Ramirez, A., Castillo, A., Alfaro, Y., de la Torre, R., & Barbanoj, M. J. (2002) · Journal of Chromatography B · doi:10.1016/s1570-0232(02)00397-5 · Cited by 113
Self-citationHypotheses Regarding the Mechanisms of Ayahuasca in the Treatment of Addictions
Liester, M. B., & Prickett, J. I. (2012) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2012.704590 · Cited by 77
Domínguez‐Clavé, E., Soler, J., Pascual, J. C., Elices, M., Franquesa, A., Valle, M., Álvarez, E., & Riba, J. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5085-3 · Cited by 94
Self-citationKiraga, M. K., Mason, N. L., Uthaug, M. V., van Oorsouw, K. I. M., Toennes, S. W., Ramaekers, J. G., & Kuypers, K. P. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.721537 · Cited by 85
Lawn, W., Hallak, J. E., Crippa, J. A., Dos Santos, R., Porffy, L., Barratt, M. J., Ferris, J. A., Winstock, A. R., & Morgan, C. J. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-14700-6 · Cited by 78
Renelli, M., Fletcher, J., Tupper, K. W., Files, N., Loizaga-Velder, A., & Lafrance, A. (2018) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-018-0619-6 · Cited by 92
Pires, A. P. S., De Oliveira, C. D. R., Moura, S., Dörr, F. A., Silva, W. A. E., & Yonamine, M. (2009) · Phytochemical Analysis · doi:10.1002/pca.1110 · Cited by 76
Changes in Spirituality Among Ayahuasca Ceremony Novice Participants
Trichter, S., Klimo, J., & Krippner, S. (2009) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2009.10399905 · Cited by 71
Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice
Payne, J. E., Chambers, R., & Liknaitzky, P. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00034 · Cited by 78
Entheogens and Existential Intelligence: The Use of Plant Teachers as Cognitive Tools
Tupper, K. W. (2002) · Canadian Journal of Education / Revue canadienne de l éducation · doi:10.2307/1602247 · Cited by 100
Maqueda, A. E., Valle, M., Addy, P. H., Antonijoan, R. M., Puntes, M., Coimbra, J., Ballester, M. R., Garrido, M., González, M., Claramunt, J., et al. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv065 · Cited by 73
Self-citationTherapeutic potential of ayahuasca in grief: a prospective, observational study
González, D., Cantillo, J., Pérez, I., Farré, M., Feilding, A., Obiols, J. E., & Bouso, J. C. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05446-2 · Cited by 75
Kikura‐Hanajiri, R., Hayashi, M., Saisho, K., & Goda, Y. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2005.01.041 · Cited by 77
van Oorsouw, K., Toennes, S. W., & Ramaekers, J. G. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06046-9 · Cited by 74
Hassan, Z., Bosch, O. G., Singh, D., Narayanan, S., Kasinather, B. V., Seifritz, E., Kornhuber, J., Quednow, B. B., & Müller, C. P. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00152 · Cited by 76
Riba, J., Rodríguez‐Fornells, A., & Barbanoj, M. J. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1237-5 · Cited by 79
Self-citationGandy, S., Forstmann, M., Carhart-Harris, R. L., Timmermann, C., Luke, D., & Watts, R. (2020) · Health Psychology Open · doi:10.1177/2055102920978123 · Cited by 63
dos Santos, R. G., & Hallak, J. E. C. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.04.053 · Cited by 56
Acute Pharmacological Effects of 2C-B in Humans: An Observational Study
Papaseit, E., Farré, M., Pérez-Mañá, C., Torrens, M., Ventura, M., Pujadas, M., de la Torre, R., & González, D. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00206 · Cited by 59
Ayahuasca: A review of historical, pharmacological, and therapeutic aspects
Ruffell, S., Crosland‐Wood, M., Palmer, R., Netzband, N., Tsang, W., Weiss, B., Gandy, S., Cowley‐Court, T., Halman, A., McHerron, D., et al. (2023) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.146 · Cited by 75
Ayahuasca: Uses, Phytochemical and Biological Activities
Estrella-Parra, E. A., Almanza-Pérez, J. C., & Alarcón-Aguilar, F. J. (2019) · Natural Products and Bioprospecting · doi:10.1007/s13659-019-0210-5 · Cited by 84
Set and Setting in the Santo Daime
Hartogsohn, I. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.651037 · Cited by 51
Herbal Highs: Review on Psychoactive Effects and Neuropharmacology
Graziano, S., Orsolini, L., Rotolo, M. C., Tittarelli, R., Schifano, F., & Pichini, S. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666161031144427 · Cited by 65
Methodology for determining major constituents of ayahuasca and their metabolites in blood
McIlhenny, E. H., Riba, J., Barbanoj, M. J., Strassman, R., & Barker, S. A. (2012) · Biomedical Chromatography · doi:10.1002/bmc.1657 · Cited by 57
Self-citationDurante, Í., dos Santos, R. G., Bouso, J. C., & Hallak, J. E. (2021) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-0913 · Cited by 49
Bringing Ayahuasca to the Clinical Research Laboratory
Riba, J., & Barbanoj, M. J. (2005) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2005.10399804 · Cited by 58
Self-citationBarker, S. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06065-0 · Cited by 58
The Pharmacology of Visual Hallucinations in Synucleinopathies
Russo, M., Carrarini, C., Dono, F., Rispoli, M. G., Di Pietro, M., Di Stefano, V., Ferri, L., Bonanni, L., Sensi, S. L., & Onofrj, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01379 · Cited by 55
The pharmacological interaction of compounds in ayahuasca: a systematic review
Ruffell, S., Netzband, N., Bird, C., Young, A. H., & Juruena, M. F. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-0884 · Cited by 45
Giovannetti, C., Garcia Arce, S., Rush, B., & Mendive, F. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1789247 · Cited by 56
Gallimore, A. R., & Strassman, R. J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00211 · Cited by 52
Binding of β-Carbolines at 5-HT 2 serotonin receptors
Grella, B. S., Teitler, M., Smith, C., Herrick‐Davis, K., & Glennon, R. A. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.027 · Cited by 56
Identification of N,N‐dimethyltryptamine and β‐carbolines in psychotropic ayahuasca beverage
Gambelunghe, C., Aroni, K., Rossi, R., Moretti, L., & Bacci, M. (2008) · Biomedical Chromatography · doi:10.1002/bmc.1023 · Cited by 52
Ayahuasca's therapeutic potential: What we know – and what not
Maia, L. O., Daldegan‐Bueno, D., Wießner, I., de Araújo, D. B., & Tófoli, L. F. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.10.008 · Cited by 61
McIlhenny, E. H., Riba, J., Barbanoj, M. J., Strassman, R., & Barker, S. A. (2011) · Biomedical Chromatography · doi:10.1002/bmc.1551 · Cited by 51
Self-citationFalchi-Carvalho, M., Palhano-Fontes, F., Wießner, I., Barros, H., Bolcont, R., Laborde, S., Silva, S. R. B., Montanini, D., Barbosa, D. C., Teixeira, E., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02091-6 · Cited by 59
Lanaro, R., Calemi, D. B. D. A., Togni, L. R., Costa, J. L., Yonamine, M., Cazenave, S. D. O. S., & Linardi, A. (2015) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2015.1013202 · Cited by 52
Rocha, J. M., Rossi, G. N., de Lima Osório, F., Bouso, J. C., de Oliveira Silveira, G., Yonamine, M., Campos, A. C., Bertozi, G., Cecílio Hallak, J. E., & dos Santos, R. G. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001396 · Cited by 46
A Critical Evaluation of Reports Associating Ayahuasca with Life-Threatening Adverse Reactions
dos Santos, R. G. (2013) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2013.785846 · Cited by 47
N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine
James, E., Keppler, J., Robertshaw, T. L., & Sessa, B. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2835 · Cited by 57
Metadata
- Authors
- Riba, J., Rodríguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M., Callaway, J. C., & Barbanoj, M. J.
- Affiliations
- Hospital de Sant Pau (ES)
- University of Eastern Finland (FI)
- Venue
- Psychopharmacology
- Published
- 2001-02-22
- Volume
- 154
- Issue
- 1
- Pages
- 85-95
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2036881116
- Cited by
- 303
- References
- 31
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 15 · 2023: 22 · 2022: 35 · 2021: 24 · 2020: 20 · 2019: 12 · 2018: 13 · 2017: 18 · 2016: 14 · 2015: 15 · 2014: 8 · 2013: 8 · 2012: 15
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- ayahuasca, N,N-dimethyltryptamine, DMT, psychedelic effects, subjective experience, tolerability, dose-response relationship, Addiction Research Center Inventory, cardiovascular effects, nausea, healthy volunteers
- MeSH terms
- Adult, N,N-Dimethyltryptamine, Hallucinogens, Hemodynamics, Humans, Male, Plant Extracts, Plants, South America, Single-Blind Method
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.